Gilead and Arcus presented mid‑stage data showing almost 27 months median overall survival for a digestive tract cancer cohort treated with an anti‑TIGIT regimen, data the companies say support their ongoing Phase 3 program versus standard of care. The results underline a sustained efficacy signal in an immuno‑oncology target that had earlier seen mixed outcomes across the field. Sponsors framed the data as justification to continue pivotal testing and refine patient selection.